Theracryf Plc (AIM:TCF)
London
· Delayed Price · Currency is GBP · Price in GBX 0.205
0.00 (0.00%)
Mar 5, 2026, 8:00 AM GMT
Theracryf Company Description
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders.
The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy.
It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders.
The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024.
Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Theracryf Plc
| Country | United Kingdom |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Huw Jones |
Contact Details
Address: Alderley Park Nether Alderley, SK10 4TG United Kingdom | |
| Phone | 44 1625 315 090 |
| Website | theracryf.com |
Stock Details
| Ticker Symbol | TCF |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | April - March |
| Reporting Currency | GBP |
| ISIN Number | GB00BSVYN304 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Huw Jones | Chief Executive Officer |
| Toni Haenninen | Chief Financial Officer |
| Helen Kuhlman | Chief Operating Officer |